The North America Analgesics Market would witness market growth of 6.1% CAGR during the forecast period (2022-2028).
Migraine is a condition that is more than just a headache. Nausea, dizziness, and eye issues are common side effects of this illness. The etiology is unknown. However, some specialists believe it is a central nervous system hereditary condition linked to epilepsy. Triptans, which function on serotonin receptors, and nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed by doctors. Preventive measures, like dietary adjustments, blood pressure medication, or anti-seizure medicines, may be required if migraines occur frequently. Analgesics can help to relieve migraine discomfort. Analgesics are necessary drugs for some people. Patients with acute serious pain, cancer pain, or pain at the end of life benefit from analgesics because they improve their quality of life. These factors would propel the growth of the analgesics market in the coming years.
Because of the rising prevalence of chronic diseases and the widespread utilization of analgesics as a pain reliever as well as for illicit purposes, the demand for analgesics is increasing in the United States. In order to meet the updated regulatory standards, the US is increasing its efforts on labeled opioid producers attempting to sell new drugs. Furthermore, because of government support for ongoing clinical research, the United States has a robust pain management sector. In addition, the significant prevalence of various major market players across the region is another factor aiding in the introduction of several new innovations across this sector. Pfizer, Purdue Pharmaceuticals, Janssen Pharmaceuticals, Assertio Therapeutics, as well as other North American companies have helped the country achieve its excellent accomplishments. Due to the development of new formulations and abuse deterrence studies, Purdue was the first company to offer opioids with abuse-deterrent properties.
The US market dominated the North America Analgesics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $11,043 Million by 2028. The Canada market is anticipated to grow at a CAGR of 8.5% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 7.5% during (2022 - 2028).
Based on Type, the market is segmented into Non-opioids and Opioids. Based on Route of Administration, the market is segmented into Oral, Transdermal, Intravenous, Topical, and Rectal. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Analgesics Market is Estimated to reach $42.6 Billion by 2028, at a CAGR of 6.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Reckitt Benckiser Group PLC, Abbott Laboratories, Johnson & Johnson, Bayer AG, Endo International PLC, GlaxoSmithKline PLC, Pfizer, Inc., Sanofi S.A., and Eli Lilly And Company.
By Type
By Route of Administration
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
